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Abstract 
 
Disorders of sex development (DSD) consist of a diverse group of conditions 
that can sometimes be challenging to diagnose accurately using standard phenotypic and 
biochemical approaches. Obtaining a specific diagnosis can be important for identifying 
potentially life-threatening associated disorders, as well as providing information to 
guide parents in the most appropriate management for their child. Recent advances in 
molecular methodologies have helped to identify several novel causes of DSD, and have 
led to the adoption of molecular tests into clinical practice for diagnosis and genetic 
counselling. Occasionally, pre-implantation diagnosis in assisted reproductive 
technology, prenatal diagnosis of at-risk pregnancies and confirmatory testing of 
positive newborn screening results is performed. Among the genetic tests available, 
most use a candidate-gene approach, while new high-throughput DNA analysis could 
enable a genetic diagnosis to be made where the aetiology is unknown or differential 
diagnosis wide. Nonetheless, genetic tests have also been associated with several 
concerns; a diagnosis is not always possible even using new molecular approaches, 
resulting in anxiety for the parents, and incidental information obtained may be a 
concern. Careful selection of the genetic test indicated for each condition remains 
important for good clinical practice. The purpose of this brief review is to describe some 
advances in molecular biological techniques for diagnosing DSD. 
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Introduction  
 
Mammalian sex development is a complex process that depends on three general 
steps.  
The first step is establishment of the chromosomal complement at fertilisation so 
that the typical male has XY chromosomes and the typical female XX chromosomes 
(sometimes referred to as “chromosomal sex”).  
The second step is gonad determination (“sex determination”). This process 
involves development of the bipotential gonad into either a testis or ovary (“gonadal 
sex”). The presence of the SRY gene on the Y chromosome is usually sufficient to 
promote testis development, whereas an ovary will usually develop in the absence of 
SRY expression1.  
The final step is differentiation of the internal and external genitalia (“sex 
differentiation”). This process occurs under the influence of hormones secreted by the 
gonad and results in the “phenotypic sex”. Early in gestation, all embryos have both 
paramesonephric ducts (Müllerian ducts) and mesonephric ducts (Wolffian ducts). If a 
testis develops, anti-Müllerian Hormone (AMH), a glycoprotein secreted from the 
Sertoli cells, acts on its receptor in the Müllerian ducts causing their regression. 
Testosterone secreted by the testicular Leydig cells acts on the androgen receptor in the 
Wolffian ducts inducing development of the epidydimis, deferent ducts and seminal 
vesicles. Testosterone is further reduced to dihydrotestosterone (DHT), which acts on 
androgen receptors to cause androgenisation (masculinisation) of the external genitalia. 
Although, the female reproductive tract develops even in the absence of any gonad, 
advances in our knowledge have demonstrated that ovarian development and its 
maintenance are active processes1. 
Mutations or alterations in the genes regulating gonad determination and sex 
differentiation can lead to disorders of sex development (DSD) 2. Based on the Chicago 
Consensus, these can be broken down into three broad categories: sex chromosome 
DSD, 46,XY DSD and 46,XX DSD. The karyotype per se does not make a child “male” 
or “female” and ideally a specific diagnosis is reached for each individual. However, the 
ability to detect an X and Y chromosome rapidly using techniques such as fluorescent 
in-situ hybridisation (FISH) means that a broad diagnostic category can be reached in 
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around 48 hours and counselling and biochemical and genetic investigations focussed 
accordingly.  
Sex chromosome DSD results from differences in sex chromosome number, and 
theoretically includes the sex chromosome aneuploidies such as Turner syndrome 
(45,X) and Klinefelter syndrome (47,XXY). Early presentation with atypical genitalia 
can occur in some children with 45,X/46,XY mosaicism or 46,XX/46,XY ovotesticular 
DSD.  
46,XY DSD results from incomplete intrauterine virilisation and is characterised 
by ambiguous or “female” external genitalia with or without the presence of Müllerian 
structures. 46,XY DSD can result from impaired production of testosterone, decreased 
conversion of testosterone into DHT or from impairment of the peripheral action of 
these hormones3. At histological analysis, testicular tissue can be absent, partially or 
completely dysgenetic, or even appear normal depending on the underlying condition4, 
5. 
46,XX DSD results from fetal exposure to androgen excess and is characterised 
by ambiguous or “male” external genitalia. Most often this is due to congenital adrenal 
hyperplasia (CAH). These patients usually have ovaries and Müllerian structures, except 
for a rare subgroup who have isolated testicular tissue (46,XX testicular DSD) or both 
testicular and ovarian tissue present (46,XX ovotesticular DSD)6.  
Although DSD can present at many different ages, one of the most common 
presentations is with ambiguous (or atypical) genitalia in the newborn period. Sex 
assignment may be a complex process and especially challenging for babies with a 
46,XY karyotype and poorly developed genitalia and non-palpable gonads7. Meticulous 
assessment and counselling by a multidisciplinary team is essential in this process. 
Reaching a specific diagnosis can be important for assessing the risk of potentially 
associated harmful conditions (e.g. renal, adrenal disorders), and to some extent 
predicting long-term outcome such as gender identity, endocrine function, potential 
fertility and gonadal tumour risk. The rapid identification of a molecular cause may 
sometimes be very helpful in decision making8. 
The purpose of this review is to analyse the contribution of and the advances in 
molecular biology techniques in the management of DSD. 
 
Molecular approaches to the diagnosis of DSD 
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Historically, candidate genes for DSD have been identified following analysis of 
deleted or duplicated chromosomal regions that segregate with DSD phenotypes (copy 
number variations)9, linkage analysis, from animal models, or when a biochemical 
profile suggests a block in a key enzyme or protein in a biochemical pathway. 
Following the identification of a potential DSD-causing gene, conventional Sanger 
sequencing has typically been used to analyse groups of patients depending on their 
phenotype and hormonal profiles. Nowadays, Sanger sequencing is still the main 
methodological tool used to investigate inherited mutations10. When there is clear 
biochemical evidence suggesting a block in a specific pathway, the chances of 
identifying a change in the relevant gene are generally high (e.g. STAR, CYP17A1, 
POR). However, where the potential cause of DSD is not clear or specifically indicated 
by the hormonal profile (e.g., testicular dysgenesis), a molecular diagnosis is only 
established in around 20% of cases using a candidate gene approach2.  
In additional to candidate gene sequencing, specific copy number variations 
(CNV) can be analysed using techniques such as FISH, quantitative PCR and multiplex 
ligation-dependent probe amplification (MLPA). In a small number of cases, 
duplications or deletions of genes or specific exons can be identified. For example, in 
46,XY gonadal dysgenesis a deletion of SRY is found in approximately 5% of cases and 
duplication of the region of Xp21 containing NR0B1 in a similar proportion 11.  
Recently, high-throughput molecular tools have allowed the simultaneous 
analysis of copy number variation or parallel sequencing of many genes with much 
greater efficiency12. Among these genetic tests, array-comparative genomic 
hybridization (array-CGH) and SNP genotyping array, whole-exome or -genome 
sequencing could enable a genetic diagnosis to be made where the differential diagnosis 
is wide, biochemical tests unclear or even in the absence of prior clinical suspicion13-15. 
Array-CGH allows rapid screening to identify submicroscopic genomic 
imbalances resulting in the identification of known and potentially causative copy 
number variations (CNVs) on a genome wide scale. It is a powerful technique with high 
potential resolution. It is becoming a routine clinical diagnostic tool and is gradually 
replacing classical cytogenetic methods in some centres. Most of the clinically available 
aCGH platforms are designed to detect aneuploidies, well-characterized 
microdeletion/microduplications and subtelomeric or other unbalanced chromosomal 
rearrangements. In addition, aCGHs cover numerous CNVs of unclear significance 
scattered throughout the human genome, some of which may be relevant especially if 
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they contain candidate genes or occur de novo. However, this technology is not able to 
identify balanced chromosomal rearrangements such as translocations and inversions 
and some ploidies16, and low level mosaicism may not be detected (Table 1). 
Furthermore, validation of the data is necessary by other techniques such as FISH, 
Multiplex Ligation-dependent Probe Amplification (MLPA) or a quantitative copy 
number variant assay16. Nevertheless, customized array-CGH platforms are becoming a 
useful tool in genetic disorders and prenatal diagnostics and have been applied to 
investigate DSD patients with 46,XY gonadal dysgenesis and with unknown cause15, 17.  
More recently, next generation sequencing (NGS) technologies have 
revolutionized the identification of disease-causing genes. These sequencing methods 
employ massively parallel approaches to sequence multiple samples simultaneously18. 
NGS is predominantly a simple DNA variant test with the ability to detect single base-
pair substitutions and small insertions and deletions involving a few nucleotides. If the 
patient´s phenotype is more consistent with a chromosome abnormality, it is more 
appropriate to perform a karyotype and/or aCGH as an initial test, although newer 
algorithms are improving the detection of CNVs from high throughput sequencing 
approaches. In addition, if a specific diagnosis is suggested from biochemical or 
hormonal data then a more focussed approach is appropriate. 
Some studies have claimed that NGS can identify variants with 99.9% 
sensitivity and specificity at a depth of 30-fold19. However, difficulties remain in terms 
of the quality and efficiency of capture methods and coverage, data transfer, storage and 
especially bioinformatic analysis. Strategies to address allelic variants of unknown 
significance should be developed. Multiple sources of error including sequencing errors, 
incorrect alignment (mismapping) and random sampling may occur in NGS, especially 
when read depth is low18.  In general, NGS cannot identify variations larger than a few 
base pairs in size, such as indels (insertions and deletions), trinucleotide repeats and 
some copy number variations20. Confirmatory Sanger sequencing or MLPA/array-based 
tests are still necessary to confirm the results of NGS if the results are being used 
clinically, which increase the cost and time to reach the diagnosis21-23. 
The three most common applications of NGS are in targeted arrays, whole 
exome sequencing (WES) and whole genome sequencing (WGS). Targeted arrays are 
designed to capture panels of known genes involved in conditions such as DSD, so that 
these genes can be sequenced at the same time and for relatively low cost. This 
approach may be useful when many different genes, some of which are quite large (e.g. 
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MAP3K1), can produce a common phenotype such as testicular dysgenesis. Sanger 
sequencing of these genes on a one-by-one basis would be laborious and costly in terms 
of manpower, and the development of targeted arrays linked to NGS might be a solution 
to screening for potentially disruptive changes (Table 1).  
WES is generally more expensive, but the cost of this approach is falling and the 
clinical application is increasing in some settings 18, 24-26. WGS is being used in some 
research settings but is currently more costly. Some of the major challenges with these 
approaches are the number of variants detected and incidental or “bystander 
information”, information that is discovered in non-relevant genes that may have health-
related consequences. For example, WES typically generates 15,000-20,000 variants 
within the coding region while WGS typically generates 3-4 million variants that differ 
from the human reference sequence 23. The vast majority of these variants are benign, 
and only 1-2% are associated with a potential phenotype. Several filters should be used 
for the selection of deleterious variants: variants with low allelic frequency (<1-5%) in a 
reference population and synonymous and noncoding variants are generally excluded, 
whereas, nonsense, frameshifts, indels and canonical splice site variants are more likely 
to be deleterious, especially if a review of the literature supports the variants’ 
pathogenicity. Indeed, incidental findings of potentially deleterious variants have been 
reported in normal populations (3.4% for European descent and 1.2% for African 
descent) so clear structures need to be in place to know what information an individual 
might want to be told and to have variants verified in a clinically approved test and with 
the support of genetic counselling27. As the cost of WES continues to drop, it can be 
envisaged that this could be a frontline test in some centres, with initial analysis of 
DSD-related genes in the first instance28. 
Another challenge of DSD is that some causes occur de novo or even in 
dominantly inherited forms, and the inability of affected individuals to reproduce means 
that large pedigrees with affected and unaffected individuals are often not available. The 
use of family trios (parents and affected child) is very important to facilitate the variant 
filtering process23, especially for detecting de novo changes. The potential significance 
of findings in novel genes is strengthened when changes in the same new gene are 
found in multiple independent families or individuals with DSD and not in large 
ancestrally-matched-population control databases. International research collaborations 
may be needed to reach this goal29. 
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Molecular approach to prenatal diagnosis of DSD  
Prenatal detection of ambiguous genitalia or genotype-phenotype discordance 
has increased over time because of the widespread use of advanced technical imaging 
and molecular approaches to determine fetal genetic sex30. A prenatal 
karyotype/phenotype discrepancy has been reported to occur in as many as 
approximately 1:2,500 pregnancies31. Ambiguous genitalia should be suspected when 
typical male or female genitalia are not visualised on prenatal ultrasound performed by 
an experienced sonographer after 14 weeks of gestation (wg). Several approaches have 
been developed over the years to determine fetal karyotype, the most recognised is the 
karyotyping of cells cultured from the CVS or amniotic fluid at approximately 11-14 to 
16 wg, respectively. However, both these procedures have small, but measurable rates 
of pregnancy loss, varying from 0.5 to 2%32,33. Amniocentesis can only be performed in 
the second trimester of gestation and, although CVS provides reliable results in the first 
trimester, its use before the 11th wg is associated with limb defects34. 
The identification of circulating cell-free fetal DNA (cffDNA) in maternal blood 
in 1997 provided an important alternative approach for noninvasive prenatal diagnosis34, 
35 and nowadays, PCR-amplification of cffDNA is the gold standard method to define 
earlier fetal sex without any risk of miscarriage 36.  
The sensitivity and specificity of fetal sexing by cffDNA can be influenced by 
methodologies, the sample types and gestational age. Different Y chromosome markers 
(SRY, DYS14) have been used for Y chromosome detection proposes37, 38. However, 
two recent meta-analysis studies did not observe discernable differences between both 
markers, with the methodology used and gestational age at sample collection being the 
main factors influencing the diagnostic accuracy of sex determination using cffDNA36, 
37.  
There is an agreement that fetal sex can only be determined with an accuracy 
close to 100%, after the 8th wg34, 36, 37, 39. However, a great debate remains in the 
literature regarding the earliest gestational age associated with the higher sensitivity and 
specificity. In a recent meta-analysis, which included 10,587 tests, the sensitivity and 
specificity at 5th wg were 93% and 95%, respectively. To avoid false-negative results, 
before reporting a test as female (Y chromosome negative), all negative tests collected 
before the 8th wg should be repeated in the following weeks40. Recently cffDNA 
analysis using NGS has been reported for the diagnosis of some monogenic or X-linked 
genetic disorders but the use in clinical practice is still limited37, 41. 
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Molecular approach to Sex Chromosomal DSD (45,X/46,XY mosaicism) 
 
DSD due to chromosomal abnormalities can include Turner Syndrome (45,X), 
Klinefelter Syndrome (47,XXY) 45,X/46,XY mosaicism (also known as mixed gonadal 
dysgenesis, MGD), and 46,XX/46,XY chimerism. Despite the fact that most children 
with a 45/46,XY karyotype have normal male phenotype at birth42, the phenotype can 
be highly variable and it is still  one of the more prevalent conditions to present with 
atypical genitalia postnatally. The most common feature in this group of children is 
asymmetric development of gonads often with a dysgenetic testis in one side and a 
streak gonad in the other43, 44. The karyotype is 45,X/46,XY or its variants with a 45,X 
cell line and one or more lineages with a normal or structural abnormal Y chromosome 
The 45,X/46,XY mosaic is also associated with short stature, cardiovascular and renal 
anomalies among other features, but different phenotypes may be determined by the 
presence of Y deletions, ring chromosomes and isochromosomes. Surveillance for 
Turner Syndrome associated features is recommended. 
Detection of an abnormal Y chromosome in routine analysis depends on the type 
and the size of the missing Y segment. Classical cytogenetic results can be 
supplemented with FISH techniques to ensure a better characterisation of chromosomal 
abnormalities. FISH can be useful in identifying the nature and the origin of unknown 
markers and chromosomal rearrangements, which may have important implications in 
sex determination and in the development of gonadal tumours45.  
 Array CGH (aCGH) represents an alternative approach to sex chromosomal 
complement analysis46. In a comparative study between SNP array analysis and 
classical karyotyping in patients with Turner Syndrome, it has been demonstrated that 
SNP array analysis can have advantages over karyotyping for the identification of 
cryptic Y chromosome material47. However, karyotyping retains an important advantage 
over arrays for the identification of complex mosaicisms, including translocations and 
rare X chromosome structural variants. SNP genotyping is unable to detect fully 
balanced X-autosome translocations, and it is currently unclear whether low level 
mosaicism will be missed 46, 47. 
Mutational analysis by NGS may also be relevant in DSD patients with sex 
chromosome mosaicism 48.  
 
Molecular approach to 46,XY DSD  
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46,XY DSD can present with a large phenotypic spectrum of features. Where 
biochemical data or the presence of associated features point to a specific single gene 
cause, traditional approaches to sequencing are usually informative. However, in many 
cases of testicular dysgenesis or the broad group of “partial androgen insensitivity”, it is 
much more difficult to reach a specific diagnosis using routine techniques. New 
molecular tools may help in the investigation of these patients (Figure 1). Occasionally, 
specific genetic investigations have been performed in fetal DNA to investigate a 
known molecular defect in families with a previously affected child49-52.  Defining the 
molecular basis of some forms of 46,XY DSD can have important clinical implications 
(Table 2). 
 
46,XY caused by abnormal gonadal determination 
Abnormalities in the expression of genes involved in the process of gonadal 
determination can disrupt testicular development. Complete and partial forms of 46,XY 
gonadal dysgenesis result from complete or partial failure of this process, respectively. 
Individuals with 46,XY complete gonadal dysgenesis (CGD) usually present in 
adolescence with absent puberty, typical female internal and external genitalia, and 
streak gonads. In contrast, partial testicular dysgenesis usually presents at birth with 
ambiguous genitalia; variable internal and external genitalia are seen53. SRY and NR5A1 
(encoding SF-1) mutations are the most frequent molecular causes of isolated 46,XY 
GD and recently variations in MAP3K1 have also been identified54. Gonadal dysgenesis 
may be isolated or may be part of a syndrome. When additional features are found, a 
candidate-gene approach is generally successful (for example, Denys-Drash Syndrome 
and WT1; heart defects and GATA4; or campomelic dysplasia and SOX9). 
Human sex development is sensitive to gene dosage effects and duplication and 
deletion events contribute to anomalies in gonadal development. Abnormal copy 
number variation or expression of several genes involved in testis determination have 
been identified in patients with 46,XY gonadal dysgenesis11. Commercial genetic tests 
to identify gene copy number variation, for SRY, SOX9, NR0B1/DAX1, DMRT1, 
NR5A1/SF1, WNT4, and WT1, and sequencing for each candidate gene are clinically 
available. Investigation of gene dosage imbalances using MLPA analysis has provided a 
good complement to DNA sequencing in patients with 46,XY gonadal dysgenesis, 
enabling simultaneous screening for deletions and duplications of several genes11, 15, 55. 
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The evaluation of the entire genome by aCGH to identify submicroscopic 
genomic imbalances on a genome wide scale, or whole-exome or -genome sequencing 
may allow molecular diagnosis of known genes and novel candidate genes for 46,XY 
gonadal dysgenesis13-15.  
For example, studies using array-CGH technique resulted in the identification of 
known or potentially causative aberrations in some patients with dysgenetic DSD15, 17, 
56. In one such report, Affymetrix Genome-Wide Human SNP Arrays 6.0 were used to 
analyse copy number variation in 23 individuals with gonadal dysgenesis without a 
genetic aetiology. Three copy number changes potentially caused gonadal dysgenesis 
were found: a large duplication on the X chromosome that included NR0B1, a 
rearrangement that appears to affect the SOX9 region and a small deletion immediately 
downstream of GATA4 suggesting that rearrangements of non-coding sequences 
disturbing gene regulation may account for a proportion of DSD cases17.  
In another study, a customized 1 M array-CGH platform with whole-genome 
coverage and probe enrichment targeting 78 genes involved in sex development was 
used to analyze 9 patients with 46,XY gonadal DSD. Three novel candidate regions for 
46,XY GD were identified in two patients: an interstitial duplication of the SUPT3H 
gene and a deletion of C2ORF80. A large duplication highlighting PIP5K1B, PRKACG 
and FAM189A2 were also detected but functional analyzes of these genes are not 
available15. 
Many studies of whole exome sequencing in patients with 46,XY due to gonadal 
dysgenesis are currently underway but, to date, published results are limited. In a pilot 
study of 10 DSD patients using exome sequencing, a molecular cause was confirmed in 
five individuals with a previous known genetic diagnosis and potentially in 2/5 patients 
in whom no molecular diagnosis could be obtained by current diagnostic approach57. 
Another report used exome sequencing to describe the first missense mutations in the 
coding sequence of FOG2 associated with 46,XY DSD in humans58. The first loss-of-
function mutation in hedgehog acyl-transferase (HHAT) was also found in a child with 
testicular dysgenesis and chondrodysplasia, due to disrupted hedgehog palmitoylation 
and signalling59. Exome sequencing has also identified disruption of known genes, such 
as NR5A1/SF-160. In a recent report, the underlying genetic etiology of 46,XY DSD 
patients without a previous genetic diagnosis was investigated by exome sequencing 
followed by analysis of a list of all known human DSD-associated genes. The 
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identification of the genetic diagnosis was possible in more than a third of cases28. It is 
likely that further reports of novel causes of DSD will emerge in the near future.  
 
46,XY DSD caused by abnormal production of testosterone 
Most cases of 46,XY DSD resulting from enzymatic defects in adrenal and/or 
gonadal steroid synthesis have a hormonal profile in basal and/or stimulated conditions 
(after ACTH or hCG stimulation tests) that indicates the causative defect of the disorder 
(e.g., 3-β hydroxysteroid dehydrogenase deficiency type 2, 17α- hydroxylase deficiency 
or 17-β hydroxysteroid dehydrogenase deficiency type 3) (Figure 1). The hormonal 
diagnosis is based on the accumulation of steroid precursors above the enzymatic defect 
and, frequently, the molecular defect can be identified by Sanger sequencing61. In two 
children with atypical genitalia due to 17β-HSD3 enzyme deficiency and normal D4/T 
ratio after hCG stimulation, Sanger sequencing disclosed mutations in the HSD17B3 
gene confirming the diagnosis of 17β-HSD3 deficiency . Therefore, molecular genetic 
analysis provides more accurate diagnosis of 17β-HSD3 deficiency than serum D4/T 
ratio 62 
 
46,XY DSD caused by androgen insensitivity 
Androgen insensitivity syndrome is the most frequently recognized 46,XY DSD 
and has a X-linked pattern of inheritance. Girls with complete androgen insensitivity 
syndrome (CAIS) present with a typical phenotype (breast development, primary 
amenorrhea and scarce pubic hair) and hormonal profile during and after puberty. 
Before puberty, there is an overlap between the CAIS phenotype and 46,XY DSD 
caused by mutations in the LHCGR, NR5A1, CYP17A1 or HSD17B3 genes 63. The 
identification of defects in these genes by sequencing may establish the diagnosis 
avoiding the need for an hCG stimulation test. In contrast, the phenotype of partial 
androgen insensitivity syndrome (PAIS) is quite variable, and the clinical presentation 
depends on the degree of responsiveness of the external genitalia to androgens. 
Ambiguous genitalia with microphallus, severe hypospadias, bifid scrotum and palpable 
gonads, is the most frequent phenotype of PAIS 64. The large phenotype spectrum of 
PAIS patients can cause misdiagnosis with several 46,XY DSDs due to defects in 
androgen production65. PAIS diagnosis is unequivocally established by the 
identification of a molecular defect in the AR gene. 
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AR mutations are identified in almost all CAIS patients and in many patients 
with PAIS66, 67. In our experience, Sanger sequencing identifies AR mutations in 89% 
and 77% of families with CAIS and PAIS, respectively. These patients were at 
pospubertal age and had typical AIS phenotype (gynecomastia, high LH and 
testosterone basal levels, affected brothers or X-linked inherited pattern). Other studies 
have suggested the prevalence of AR mutations in individuals with a “PAIS”-like 
phenotype is considerably lower68. 
The knowledge of the AR defect may not indicate the potential androgen 
responsiveness in puberty because the phenotype depends on the residual mutant AR 
function that may be influenced by different factors, such as co-regulatory proteins69. A 
NGS approach may allow the opportunity to identify genetic modifiers, although these 
are difficult studies to perform with certainty, unless large kindred are available21. 
 
46,XY DSD caused by 5α-reductase type 2 (5α-RD2) deficiency 
The biochemical diagnosis of 46,XY DSD caused by 5α-reductase type 2 (5α-
RD2) deficiency is based on an elevated serum testosterone (T)/dihydrotestosterone 
(DHT) ratio. To determine the T/DHT ratio correctly, DHT should be measured using a 
very specific assay, as the commercial immunoassays show high cross-reactivity with 
testosterone. The analytical performance of DHT assays has improved with LCMS-
based technology but this methodology is not available in most laboratories70. To 
analyse this ratio, T should be in the post-pubertal range. Therefore, in pre-pubertal 
patients, it is necessary to increase testosterone levels using hCG stimulation or 
exogenous testosterone enanthate injection71, 72. However, especially in newborns, a 
normal T/DHT ratio does not exclude 5α-RD2 because the transcription of the 
isoenzyme 5α-RD1, normally not detected at this age, may occur73, 74. Considering the 
prevalence of normal T/DHT ratios in affected patients, mutational analysis of the 
SRD5A2 gene is indicated as the first approach especially in neonates75, 76. This is 
clinically important as the diagnosis of a SRD5A2 gene mutation in neonates with 
ambiguous genitalia may influence the choice of sex-of-rearing based on the significant 
association of 5α-RD2 deficiency with a change to male social sex. Moreover, many 
adults with 5α-RD2 deficiency reared as male report a statistically significant better 
quality of life than adults reared as females 77, 78. In addition, male patients may possibly 
have children after intrauterine insemination79. 
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46,XY DSD of unknown aetiology 
Despite advances in our knowledge of the genetic basis of sex development a 
significant number of people with 46,XY DSD do not have an aetiologic diagnosis. In 
these patients, chromosomal abnormalities are not identified by classical cytogenetic 
techniques and the hormonal profile is not suggestive of the causative disorder. In this 
group of patients without a suspected target gene, next generation sequencing 
techniques may allow the identification of novel or unsuspected known genes associated 
with DSDs, especially if there are multiple affected family members. Studying trios will 
be important, especially for identifying de novo changes, and multicentric and 
international collaborative approaches may identify multiple variants in the same gene 
in independent families, which will be useful especially if supported by gene/protein 
expression data or animal models. However, proving causation in some cases may be 
challenging, especially if there are strong modifier effects from other genetic/oligogenic 
or epigenetic influences, or from environmental effects. Defining monogenic disorders 
may become increasing more difficult and, as we enter a grey area, we may find a 
subset of conditions where there are strong genetic associations, weak genetic 
associations, or where no apparent genetic association (at least on the exome level) 
exists. 
 
Molecular approaches to 46,XX DSD  
 
CAH due to 21 hydroxylase deficiency 
The diagnosis of 21-hydroxylase deficiency is essentially based on 
measurements of adrenal steroids, and markedly increased serum 17OH-progesterone 
levels in a baby with ambiguous genitalia define the diagnosis of classical form. 
However, molecular methodologies can be useful in specific conditions, such as in male 
newborns with normal genitalia and moderately increased 17OH-progesterone levels, to 
allow differential diagnosis of classical and non-classsical forms of CAH, with 
therapeutic implications 80. 81, 82.  
One of the most recognized uses of molecular biology is for the diagnosis and 
treatment of at-risk pregnancies. This therapy has been used in tertiary centres for over 
30 years and has been proven effective in reducing genital virilisation of affected female 
fetuses with CAH83, 84, 85. In brief, this treatment involves administration of 
dexamethasone (DEX), in order to suppress the adrenal androgen secretion. The success 
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of treatment depends on its onset, ideally no later than the 7 wg, before the period of 
genital sensitivity to androgen action, and is maintained until the end of pregnancy in 
affected fetuses84.  
In an attempt to avoid DEX exposure of all male fetuses and in unaffected 
female fetuses, new approaches for prenatal diagnosis have been developed. Despite the 
descriptions that fetal sex determination using cffDNA have the highest sensitivity and 
specificity at 8 wg, recently a representative series with 258 at-risk pregnancies for 
CAH described a sensitivity of 96% for identification of Y-chromosomal material at the 
4 wg86. 
More recently, attempts to determine earlier CYP21A2 genotype in cffDNA, to 
minimize the time of DEX exposure in female fetuses, have been proposed.87. NGS of 
cffDNA in maternal plasma, at 5.4 wg, allowed the diagnosis of affected and unaffected 
female fetuses by linkage analysis of SNPs flanking the CYP21A2 87.  
Despite these advances,  prenatal DEX therapy cannot be considered a standard 
care, and some adverse effects have been observed. Prenatally treated children have  
birth weight within the normal range, but reduced by approximately 0.4-0.6 kg, and the 
long term significance of this finding remains of concern88.  In another study, unaffected 
children treated prenatally with DEX had poorer verbal working memory, rated lower 
on self-perception of scholastic competence and had increased self-rated social anxiety 
89. Until the long term risks can be defined, prenatal DEX therapy should be performed 
only in tertiary centers that can follow all exposed children for long periods90.Fully 
informed consent from parents is needed.  
 
Other CAH Diagnoses 
Besides 21OH deficiency, other adrenal enzymatic defects can also present with 
moderately increased neonatal 17OHP levels and occasionally these patients are picked 
up in 21OHD neonatal screening programs, such as 3β-hydroxysteroid dehydrogenase 
deficiency type 2 (3βHSD2) and P450 oxidoreductase deficiency (POR)91-94. Molecular 
analysis can be useful as a confirmatory test in these patients91-94. Indeed, in POR 
deficiency, both sexes can present with ambiguous genitalia. Additionally, POR 
deficiency can be associated with Antley-Bixler syndrome; however, these clinical 
manifestations may be not evident at birth or may even be absent95.  
 
46,XX testicular DSD and ovotesticular DSD 
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Patients with 46,XX testicular DSD and male genitalia often have a translocated 
SRY gene, but the genetic basis of other forms of 46,XX testicular DSD (with 
ambiguous genitalia) or ovotesticular DSD is less well established96-98. 
However, a common molecular origin for these conditions is suggested based on 
families in which patients with these two phenotypes are identified 99. To date, genetic 
aetiologies of ovotesticular DSD include translocation of SRY in a small number of 
these patients, inactivating mutations in single genes (such as RSPO1, with 
palmoplantar hyperkeratosis and predisposition to squamous cell skin tumours) and 
disruption of regulatory regions resulting in altered expression of genes involved in 
testis determination (such as SOX9 and SOX3)100-102. 
Prenatal diagnosis of 46,XX testicular DSD has been reported in isolated cases, 
in which a discrepancy between the karyotype and genitalia was observed during 
screening for chromosomal aberrations96, 103. FISH analysis of amniotic fluid cells could 
be useful to identify SRY, as well as PCR amplification of the SRY sequence in fetal 
DNA samples103. 
Although ovotestes most commonly occur with a 46,XX karyotype, they can 
occur with 46,XX/46,XY chimerism or more rarely in an individual with a 46,XY 
karyotype with disruption of testis-determining genes. For example, results of high-
resolution array-comparative genomic hybridization (CGH) reported a female patient 
with 46,XY ovotesticular DSD with testicular tissue on one side and an ovary harboring 
germ cells on the other, who had a deletion of ∼35 kb affecting exons 3 and 4 of the 
DMRT1 gene. This report suggests that DMRT1 haploinsufficiency is sufficient to cause 
46,XY gonadal dysgenesis and 46,XY ovotesticular DSD104.  
 
Genetic counselling 
 
Genetic counselling is the process by which parents or relatives at risk of DSD 
are informed of the nature and consequences of the disorder, and the probability of 
developing it or and of passing it on to their offspring. The optimal time to determine 
the genetic risk and discuss prenatal testing is before pregnancy105. Family members at 
risk of an autosomal recessive or X-linked form of 46,XY DSD can be tested after the 
identification of a specific molecular defect in an affected family member. Prenatal 
genetic testing can show that the fetus is unaffected by the disorder or give parents the 
opportunity to prepare themselves for the birth of a child who has a genetic condition106. 
17 
 
Nonetheless, genetic tests are also associated with several concerns; parents 
experience stress and anxiety regarding the results, and a specific molecular diagnosis is 
not always possible, especially in 46,XY DSD. Parents carrying mutations may feel 
guilty about their child’s condition and psychological support is an important 
component of genetic counselling. 
Additionally, genetic tests are generally expensive and can cause discrimination 
and stigmatisation. For these reasons, genetic testing should be requested after an 
extensive discussion about how the result may be useful for patients, their relatives or 
for management decisions29, 107. A geneticist with experience of DSD is an invaluable 
member of the DSD team. 
 
Conclusion 
 
Recent methodological advances in the diagnosis of monogenic diseases have 
not only elucidated the molecular aetiology of patients with DSD, but also yielded 
valuable information on biological processes of sex development. Although many of 
these techniques are not yet available for routine diagnosis, in the near future they will 
likely contribute to the diagnosis of DSD in many patients quickly and inexpensively. 
However, careful selection of the genetic test indicated for each condition is still 
important for good clinical practice. Multidisciplinary approaches including 
psychological support are essential to prevent unnecessary stress during this challenging 
process. 
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Figure Legends 
 
Figure 1-Molecular approach for genetic diagnosis of individuals with 46,XY 
disorders of sex development (DSDs). 46,XY DSD results from incomplete intrauterine 
virilisation due to defects in testosterone production, androgen action or metabolism, or 
due to undetermined causes. This chart indicates a potential sequence of the molecular 
approaches to define the genetic aetiology of 46,XY DSD. The arrows indicate the steps 
of investigation based on previously described molecular defects associated with 46,XY 
DSD. In testosterone production defects, and androgen action or metabolism defects, 
the candidate-gene approach is usually the first step. Human sex development is 
sensitive to gene dosage effects and duplication and deletions events may be ruled out 
in gonadal dysgenesis, as well as obvious single gene conditions due to associated 
syndromes. Considering the low frequency of diagnosis throughout a candidate gene 
approach, aCGH and NGS should be the first step of molecular investigation in isolated 
gonadal dysgenesis as well as in undetermined DSD, unless associated features are 
present. Targeted array based approaches, and whole-exome or -genome sequencing 
may enable molecular diagnosis to be reached involving known genes and novel 
candidate genes for 46,XY. 
Abbreviations to be included under Figure 1 
aCGH: array comparative genomic hybridisation; NGS: next generation sequencing  
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Table 1: Molecular techniques applied to identify genetic causes of DSD 
 
Note: approximate costs are given in pounds sterling (January 2015). Prices vary greatly depending on the type of 
test, laboratory/country and turn around time. Clinical testing is generally more expensive and some clinical high 
throughput analysis needs validation of key findings before test results can be reported.  
 
CGH: array comparative genomic hybridization; CNV: copy number variation; LOH: loss 
of heterozygosity; MLPA: Multiplex Ligation-dependent Probe Amplification; qPCR: 
quantitative PCR SNPs: single nucleotide polymorphisms; SNVs: single nucleotide 
variants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular Technique Application 
Time to get 
data without 
analysis 
(day) 
Availability Approximate costs Limitations 
aCGH, 
SNP array CGH 
CNVs, 
Mosaicisms, 
uniparental 
disomy, LOH 
Up to 4 
Clinical & 
Research 
£250 
(N.B Standard clinical FISH 
for SRY/XCEN probes 
£150; standard clinical G-
banded karyotype £200) 
Unable to detect 
balanced 
translocations, 
inversions without loss 
of genomic material 
and polyploidies 
(triploidy and 
tetraploidy) 
Sanger Sequencing 
SNVs, small 
indels, 
microsatellite 
analysis 
Up to 2 (most 
clinical tests 
longer) 
Clinical & 
Research 
£150-£600 (clinical testing 
depending on the size of the 
gene, laboratory and turn 
around time; targeted 
sequencing of known 
changes in a family less 
expensive) 
Does not detect large 
deletions or insertions 
and can only analyze 
specific and small 
regions at a time, labor 
intensive 
qPCR 
CNVs, SNPs, 
gene expression 
1.5 
Clinical & 
Research 
£150 
Analyze specific and 
small regions at a time 
MLPA 
CNVs, SNPs 
methylation 
defects 
Up to 3 
Clinical & 
Research 
Variable depending on panel 
Analyze specific and 
small regions at a time 
Next 
Generation 
Sequencing 
Targeted 
Custom 
Capture 
Array 
SNVs, CNVs Up to 4 
Clinical & 
Research 
£800 (DSD clinical panel, 
including validation of 
positive findings); 
£800 (multigene clinical 
panel, including most DSD-
related genes, including 
validation of positive 
findings); 
£130 (research panel of 150 
genes, not including labour 
costs for processing or 
analysis, or clinical 
validation) 
High cost, labor 
intensive, bioinformatic 
support needed, may 
not detect moderate 
insertions and 
deletions, “bystander” 
information about other 
genes may be obtained  
Exome SNVs, CNVs, Up to 16 Research 
£500-£900 (depending on 
sequencing depth and cost of 
bioinformatic analysis) 
Whole 
Genome 
SNVs, CNVs, Up to 21 Research Research 
26 
 
Table 2: Selected examples where a genetic/chromosomal diagnosis can influence clinical 
management 
 
WAGR, Wilms tumour-Aniridia-Genitourinary-Retardation; QoL, quality of life; SV, simple virilising 
 
Condition (Gene) Challenge Benefit of genetic diagnosis 
45,X/46,XY mosaicism 
Variable phenotype; associated 
features;  significant risk of 
germ cell neoplasia 
Screening for cardiac and renal anomalies and Turner 
Syndrome surveillance; growth monitoring; gonadal 
biopsies on account of tumor risk 
Chromosomal deletion 
(e.g 11p13/WAGR, 
10q, 9p) 
Associated features including 
another organ systems; potential 
learning difficulties 
Focused screening of other systems depending on the 
condition (e.g. eyes, renal, cardiac); close monitoring 
by child development team and early support and 
intervention if developmental delay occurs; 
counselling of family and contact with appropriate 
support groups and multidisciplinary services for 
children with complex needs 
Denys-Drash Spectrum 
(WT1) 
Risk of Wilms’ tumor or 
nephropathy; significant risk of 
germ cell neoplasia 
Defines individuals who need regular screening for 
Wilms’ tumor or who might develop a renal 
phenotype later; higher risk of germ cell tumors, so 
gonadectomy or careful monitoring is required 
Steroidogenic factor-1 
(NR5A1) 
Variable phenotype; potential 
primary ovarian insufficiency 
(POI) or progressive infertility 
in family members; potential 
associated adrenal disease 
Monitoring adrenal function; identifying female 
relatives who are at risk of developing POI and who 
could benefit from counseling and monitoring of 
ovarian function; identification of male relatives who 
may have infertility or a progressive endocrinopathy 
17α-hydroxylase 
deficiency 
(CYP17A1) 
Associated hypokalaemia, 
hypertension 
Allows treatment and prevention of biochemical and 
blood pressure effects 
5α-reductase 2 
deficiency 
(SRD5A2) 
Often associated with social sex 
change in puberty, potentially 
better QoL as male than female 
in adulthood; possible fertility in 
males 
Male sex assignment avoids social sex change and 
potentially better QoL 
21-hydroxylase 
deficiency 
(CYP21A2) 
Risk of salt wasting in children 
with 21-hydroxylase deficiency 
identified in neonatal screening 
Allows genetic counselling and withdrawn of 
mineralocorticoid and salt replacement in patients 
with SV form 
